<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368314</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-080-2</org_study_id>
    <nct_id>NCT02368314</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries</brief_title>
  <official_title>International Multicenter Randomized Double-blind Comparative Clinical Trial of Safety and Efficacy of BCD-080 (JSC BIOCAD, Russia) and Clexan® (Sanofi Aventis France, France) for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to prove equivalence of efficacy and safety of BCD-080 and Clexan
      for deep vein thrombosis and embolism prophylaxis at orthopedic surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 116 patients who are planned for hip or knee replacement. Patients
      will randomized in 2 groups. 1-st group will receive BCD-080 at dose 30 mg every 12 hours
      during 14 days after surgery, 2-d group will receive Clexane at the same dose. Efficacy
      assessment will include frequency of deep vein thrombosis (DVT) (proximal and/or distal;
      symptomatic or asymptomatic), symptomatic nonlethal thromboembolia of the pulmonary artery
      (PATE) and venous thromboembolism death. Safety assessment will include frequency of &quot;big&quot;,
      &quot;small&quot; and other bleedings and frequency of heparin induced thrombocytopenia.The assessment
      of efficacy and safety parameters will be made during the treatment and follow-up period
      (till 60 day).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of DVT.</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
    <description>Frequency of deep vein thrombosis (DVT) (proximal and/or distal; symptomatic or asymptomatic).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Symptomatic Nonlethal Thromboembolia of the Pulmonary Artery (PATE)</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Venous Thromboembolism Death</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of DTV</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
    <description>Frequency of DTV (proximal and/or distal; symptomatic or asymptomatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Proximal DVT</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
    <description>Frequency of proximal DVT (symptomatic or asymptomatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Distal DVT</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
    <description>Frequency of distal DVT (symptomatic or asymptomatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Symptomatic Nonlethal PATE</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Venous Thromboembolism Death</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Death From Other Causes</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Venous Thromboembolism (PATE and/or DTV)</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of &quot;Big&quot; and Clinically Significant &quot;Small&quot; Bleedings</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of &quot;Big&quot; Bleedings</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Clinically Significant &quot;Small&quot; Bleedings</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Clinically Significant Bleedings</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Other &quot;Small&quot; Bleedings</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of All Bleedings</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Heparin Induced Thrombocytopenia</measure>
    <time_frame>During the treatment period (14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Strokes, Myocardial Infarction, Unstable Angina and Cardiovascular Death</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Other AE SAE</measure>
    <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>BCD-080</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clexane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Enoxaparine</intervention_name>
    <description>30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
    <arm_group_label>BCD-080</arm_group_label>
    <arm_group_label>Clexane</arm_group_label>
    <other_name>Clexane (Sodium Enoxaparine)</other_name>
    <other_name>BCD-080 (Sodium Enoxaparine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Age ≥18 years and age ≤80 years

          3. Women body mass 50-110kg, men body mass 57-110 kg inclusive

          4. Patients who are planned for hip or knee replacement

          5. Willingness of patients of both sexes and their sexual partners with preserved
             reproductive function to use reliable methods of contraception, starting from
             screening and up to 4 weeks after the last dose of the studied drug. This requirement
             does not apply to patients who underwent surgical sterilization. Reliable methods of
             contraception involves a 1-barrier method combined with one of the following:
             spermicides/oral contraceptive

          6. Ability of the patient, in the opinion of the investigator, to meet the Protocol
             requirements.

        Exclusion Criteria:

          1. Hypersensitivity to the components included in the formula of preparation BCD-080
             (CJSC BIOCAD) Clexane (Sanofi-Avensis France, France) or medications of the same class

          2. Conditions and diseases in which there is a high risk of bleeding: cerebral aneurysm
             or aortic dissection, hemorrhagic stroke (including in history)

          3. Intractable hemorrhage

          4. History of documented diseases of blood coagulation (hemophilia A or B, Willebrand
             disease and other coagulopathies, idiopathic thrombocytopenic purpura, Heparin induced
             thrombocytopenia associated with thrombosis or without it, thrombohemorrhagic
             syndrome, etc.) in anamnesis and/or at the moment of examination

          5. Gastric or duodenal ulcer or other erosive and ulcerative lesions of gastrointestinal
             tract

          6. Recent ischemic stroke

          7. Uncontrolled severe hypertension; that is, all cases of hypertension, in which blood
             pressure decrease cannot be achieved with the use of combination of 3 antihypertensive
             drugs, compulsorily including a diuretic, and non-drug methods of correction
             (salt-free diet, graduated exercise); or if the results of two successive measurements
             of supine arterial blood pressure with an interval of 15-30 minutes, systolic blood
             pressure&gt; 180 mm Hg. or diastolic blood pressure&gt; 105 mm Hg

          8. Diabetic or hemorrhagic retinopathy

          9. Decompensated diabetes mellitus, diabetes mellitus complications

         10. Recent delivery (during last 90 days)

         11. Bacterial endocarditis (acute or subacute)

         12. Pericarditis and pericardial effusion

         13. Renal and/or hepatic insufficiency

         14. Intrauterine contraception

         15. Surgeries or injuries of brain/spinal cord, spine, eyes, and major surgeries and
             injuries within 90 days prior to randomization)

         16. Spinal surgeries or its deformation in history of patients who are planned for
             epidural/spinal anesthesia

         17. Active liver diseases

         18. Anamnestic information about alcoholism, addiction or drug abuse over the last year

         19. Contraindications to surgeries

         20. Hemoglobin &lt;100 g/l

         21. Platelet count &lt;100х10*9/l

         22. Creatine clearance &lt;30 ml/min

         23. Biochemical blood assay indexes: AST/ALT &gt; UNLх3; total bilirubin &gt; UNLх1,5 (unless
             other causal factors provided, such as Gilbert's syndrome)

         24. Necessity for continued treatment with anticoagulants (except for planned under this
             study), antiaggregant and fibrinolytics (eg, patients with artificial cardiac valve,
             atrial fibrillation patients receiving warfarin, etc.)

         25. The use of dextrans or fibrinolytic therapy or other drugs affecting hemostasis;

         26. Necessity for use of systemic glucocorticosteroids and non-steroidal anti-inflammatory
             drugs (except for the use of the latter with the purpose of anaesthesia in the early
             postoperative period - during 3 days after the planned hip or knee replacement)

         27. Impossibility of contrast venography: contrast allergy, inability to install an
             intravenous catheter, etc

         28. Pregnancy, lactation period

         29. Donation of 450 ml or more of blood or plasma within 60 calendar days before inclusion
             enrolment

         30. Participation in clinical trials no less than 30 days before enrolment into this study
             or previous participation in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashot Agahanyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Railroad Clinical Hospital at the station Chelyabinsk, Chelyabinsk, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavel Andreev, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Railroad Clinical Hospital at the station Samara, Samara, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ildar Ahtyamov, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>State budget institution of further education &quot;Kazan State Medical Academy&quot; the Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valery Zagrekov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nizhny Novgorod Research Institute of Traumatology and Orthopedics of Public Health Ministry of Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maxim Lucenko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Treatment and rehabilitation center of Public Health Ministry of Russian Federation, Moscow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Sitnik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Institution &quot;Republican Scientific and Practical Centre for Traumatology and Orthopedics&quot; of the Ministry of Health of the Republic of Belarus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Railroad Clinical Hospital at the station Chelyabinsk</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.biocad.ru</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <results_first_submitted>March 31, 2016</results_first_submitted>
  <results_first_submitted_qc>August 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2016</results_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep vein thrombosis</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Sodium enoxaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-080</title>
          <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
        </group>
        <group group_id="P2">
          <title>Clexane</title>
          <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population for analysis of safety: all patient who received at least 1 study drug injection.</population>
      <group_list>
        <group group_id="B1">
          <title>BCD-080</title>
          <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
        </group>
        <group group_id="B2">
          <title>Clexane</title>
          <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.50" lower_limit="53.00" upper_limit="63.50"/>
                    <measurement group_id="B2" value="60.00" lower_limit="53.00" upper_limit="65.00"/>
                    <measurement group_id="B3" value="58.00" lower_limit="53.00" upper_limit="64.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of DVT.</title>
        <description>Frequency of deep vein thrombosis (DVT) (proximal and/or distal; symptomatic or asymptomatic).</description>
        <time_frame>During the treatment period (14 days)</time_frame>
        <population>Patient who finished the study as per protocol and had contrast venography results for efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-080</title>
            <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
          </group>
          <group group_id="O2">
            <title>Clexane</title>
            <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of DVT.</title>
          <description>Frequency of deep vein thrombosis (DVT) (proximal and/or distal; symptomatic or asymptomatic).</description>
          <population>Patient who finished the study as per protocol and had contrast venography results for efficacy evaluation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Symptomatic Nonlethal Thromboembolia of the Pulmonary Artery (PATE)</title>
        <time_frame>During the treatment period (14 days)</time_frame>
        <population>Patient who finished the study as per protocol and had contrast venography results for efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-080</title>
            <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
          </group>
          <group group_id="O2">
            <title>Clexane</title>
            <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Symptomatic Nonlethal Thromboembolia of the Pulmonary Artery (PATE)</title>
          <population>Patient who finished the study as per protocol and had contrast venography results for efficacy evaluation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Venous Thromboembolism Death</title>
        <time_frame>During the treatment period (14 days)</time_frame>
        <population>Patient who finished the study as per protocol and had contrast venography results for efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-080</title>
            <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
          </group>
          <group group_id="O2">
            <title>Clexane</title>
            <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Venous Thromboembolism Death</title>
          <population>Patient who finished the study as per protocol and had contrast venography results for efficacy evaluation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of DTV</title>
        <description>Frequency of DTV (proximal and/or distal; symptomatic or asymptomatic)</description>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Proximal DVT</title>
        <description>Frequency of proximal DVT (symptomatic or asymptomatic)</description>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Distal DVT</title>
        <description>Frequency of distal DVT (symptomatic or asymptomatic)</description>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Symptomatic Nonlethal PATE</title>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Venous Thromboembolism Death</title>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Death From Other Causes</title>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Venous Thromboembolism (PATE and/or DTV)</title>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of “Big” and Clinically Significant “Small” Bleedings</title>
        <time_frame>During the treatment period (14 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of “Big” Bleedings</title>
        <time_frame>During the treatment period (14 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Clinically Significant “Small” Bleedings</title>
        <time_frame>During the treatment period (14 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Clinically Significant Bleedings</title>
        <time_frame>During the treatment period (14 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Other “Small” Bleedings</title>
        <time_frame>During the treatment period (14 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of All Bleedings</title>
        <time_frame>During the treatment period (14 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Heparin Induced Thrombocytopenia</title>
        <time_frame>During the treatment period (14 days)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Strokes, Myocardial Infarction, Unstable Angina and Cardiovascular Death</title>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Other AE SAE</title>
        <time_frame>During the treatment period (14 days) and follow-up period (till 60-th day)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCD-080</title>
          <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
        </group>
        <group group_id="E2">
          <title>Clexane</title>
          <description>Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
Sodium Enoxaparine: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection of surgery wound surface</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Large trochanter fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hemorrhagic discharge from surgical wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Elevated D-dimer</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Increase of activated partial thromboplastin time</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated gamma glutamyl tranferase</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema of lower limbs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biryulin Andrey</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7812380 49 33 ext 925</phone>
      <email>biryulin@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

